Drug Combination Details
| General Information of the Combination (ID: C06881) | |||||
|---|---|---|---|---|---|
| Name | Ginsenoside compound K NP Info | + | Cytarabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | Ratio of dCKappa to CDA | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| C2C12 | CVCL_0188 | Healthy | Mus musculus | |||
| HAECT-1 | CVCL_VU17 | Healthy | Homo sapiens | |||
| RAW 264.7 | CVCL_0493 | Mouse leukemia | Mus musculus | |||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Ara-C combined with CK could achieve the efficacy of higher concentration of ara-C. CK promoted ara-C-induced cell membrane damage and mitochondrial dysfunction and increased ara-C-induced DNA damage. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells. Biomed Pharmacother. 2020 Dec;132:110812. | |||
